Immuron Ltd (ASX:IMC) will collaborate with the Walter Reed Army Institute of Research (WRAIR) in the U.S to develop a vaccine to fight the often deadly Shigellosis, also known as bacillary dysentery.
There is currently no approved vaccine for bacillary dysentery, which is ranked number two in the 2015 Global Rank List of Infectious Disease Threats for the U.S. military.
It also results in one million deaths annually - according to a World Health Organisation report.
The symptoms include diarrhea (often bloody), fever and stomach cramps starting a day or two after exposure.
Based in Silver Spring, Maryland, and established in 1893, the Walter Reed Army Institute of Research (WRAIR)
is the oldest, largest, and most diverse military biomedical research institute within the U.S. Department of Defense.
The research and development collaboration agreement with the largest military biomedical research facility in the U.S. highlights the promise of Immuron’s oral immunotherapy platform.
One of WRAIR’s missions is to develop therapeutics for the prevention and the treatment of infectious diseases.
The long term goal of this collaboration is to develop therapeutics that can be utilized for both commercial and government use.
Immuron generated growing revenues from OTC products of $1.1 million in FY2015 and the company has forecast that its Travelan product will generate revenues of $4.6 million in FY 2017.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.